- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma
September 29th 2012, 3:42pm
Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.
Gefitinib: Small Benefit as Second-Line Therapy in Esophageal Cancer
September 29th 2012, 3:27pm
Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.
Multikinase Inhibitor Prolongs Progression-Free Survival in MTC
September 25th 2012, 12:25pm
Annual Meeting of the American Thyroid Association
Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.
Photos From the American Thyroid Association Annual Meeting
September 25th 2012, 11:36am
Annual Meeting of the American Thyroid Association
Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.
Dr. Sippel on the Importance of the Initial Surgery for MTC
September 25th 2012, 9:05am
Annual Meeting of the American Thyroid Association
Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.
Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer
September 24th 2012, 2:15pm
Annual Meeting of the American Thyroid Association
The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.
BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential
September 24th 2012, 12:13pm
Annual Meeting of the American Thyroid Association
Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.
Coverage From the 2012 NCONN Conference
September 23rd 2012, 2:03pm
OncLive presents live coverage from the 2012 NCONN Changing the Face of Cancer Care Conference, held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, TN.
Dr. Haugen Describes the 82nd Annual ATA Meeting
September 21st 2012, 2:35pm
Annual Meeting of the American Thyroid Association
Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.
Dr. Nikiforov on Molecular Testing of Thyroid Nodules
September 21st 2012, 2:21pm
Annual Meeting of the American Thyroid Association
Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.
Blanket Approach to RAI in PTC Patients May Not Be Necessary
September 21st 2012, 12:56pm
Annual Meeting of the American Thyroid Association
A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.
Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies
September 21st 2012, 12:00pm
Annual Meeting of the American Thyroid Association
The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.
Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure
September 21st 2012, 9:03am
Annual Meeting of the American Thyroid Association
The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.
Conference Coverage From the 2012 ESMO Congress
September 20th 2012, 12:12pm
Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.
Dr. Spigel Discusses the Evolving NSCLC Treatment Landscape
September 14th 2012, 2:10pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.
Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat
September 14th 2012, 10:57am
Chicago Multidisciplinary Symposium in Thoracic Oncology
Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.
Targeted Therapy Combination Slows NSCLC
September 14th 2012, 8:30am
Chicago Multidisciplinary Symposium in Thoracic Oncology
Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.
Mutation Confers Anti-EGFR Resistance
September 14th 2012, 6:13am
Chicago Multidisciplinary Symposium in Thoracic Oncology
A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.
Hint of Survival Benefit in NSCLC With Bavituximab Plus Docetaxel
September 13th 2012, 1:57pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.
The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
September 8th 2012, 2:37pm
Chicago Multidisciplinary Symposium in Thoracic Oncology
A brief introduction to the topics and focus of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.